PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the House Committee on Energy and Commerce.
Congressional Research Service
Version 00 · Introduced in House · Feb 7, 2025
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish drug adherence guidelines for covered drugs under Medicare so as to achieve an adherence rate of 90%. The CMS must incorporate artificial intelligence and machine-learning technologies and promote generics and biosimilars when developing the guidance.
People & committees
Rep. Schweikert, David [R-AZ-1] · R–AZ
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We also preserved the text version used in the PlainBill explanation below.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Jun 4, 2025. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.1142 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.1142 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.1142 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.1142 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.
PlainBill explanation
Based on the full Introduced in House · 2025-02-07 text. This explanation has not received human editorial review. This overview describes the proposal’s major provisions; it does not establish what its real-world effects would be.
This proposal would require federal guidelines aimed at helping people take medicines as prescribed, with a goal of 90 percent adherence for all Medicare Part B and Part D drugs. The guidelines would incorporate artificial intelligence and machine learning and, as far as practicable, promote generic medicines and biosimilars—medicines similar to existing biological medicines. The 90 percent figure is a goal, not a guaranteed result.
(a) In general The Secretary shall establish drug adherence guidelines with the goal of achieving 90 percent adherence for all Medicare part B and D drugs.
(b) Contents In establishing the guidelines under subsection (a), the Secretary shall— (1) incorporate artificial intelligence and machine learning technologies; and (2) to the maximum extent practicable, promote the use of generic and biosimilar drugs.
Section 1 would add a new section 1712 to the Public Health Service Act. It would place responsibility for establishing the drug adherence guidelines on the Secretary.
Title XVII of the Public Health Service Act (42 U.S.C. 300u et seq.) is amended by inserting after section 1711 (42 U.S.C. 300u–16) the following: 1712. Establishment of drug adherence guidelines
The Secretary shall establish drug adherence guidelines with the goal of achieving 90 percent adherence for all Medicare part B and D drugs.
When establishing the guidelines, the Secretary would have to incorporate artificial intelligence and machine learning technologies—computer methods used to analyze information and learn patterns from data.
(b) Contents In establishing the guidelines under subsection (a), the Secretary shall— (1) incorporate artificial intelligence and machine learning technologies;
The Secretary would also have to promote generic and biosimilar drugs when establishing the guidelines, but only to the maximum extent practicable.
(b) Contents In establishing the guidelines under subsection (a), the Secretary shall— (1) incorporate artificial intelligence and machine learning technologies; and (2) to the maximum extent practicable, promote the use of generic and biosimilar drugs.
For these guidelines, a Medicare Part B drug would include any drug or biological product eligible for payment under Part B. A Medicare Part D drug would have the existing statutory meaning of a covered Part D drug.
(1) Medicare part b drug The term Medicare part B drug means a drug or biological product for which payment may be made under part B of title XVIII of the Social Security Act (42 U.S.C. 1395j et seq.).
(2) Medicare part d drug The term Medicare part D drug means a covered part D drug (as defined in section 1860D–2(e) of the Social Security Act (42 U.S.C. 1395w–102(e))).
The supplied actions snapshot, updated June 4, 2025, records introduction in the House and referral to the House Committee on Energy and Commerce on February 7, 2025.
Source snapshot updated 2025-06-04T19:11:16Z. 2025-02-07: Referred to the House Committee on Energy and Commerce. 2025-02-07: Introduced in House
A closer look
Reviewed version: Introduced in House · 2025-02-07. These findings describe provisions and who may benefit; they are not judgments of waste, corruption, or motive.
This review covers the supplied bill text. “None identified” does not rule out provisions in later versions or accompanying reports and disclosures.
Provisions outside the bill’s main subject, or policy changes attached to appropriations.
None identified in the reviewed text
No unrelated provision or policy attached to appropriations was identified in the complete supplied introduced text. This conclusion is limited to that version and does not establish absence in other versions or accompanying materials.
Spending directed to particular recipients or places outside ordinary competitive or formula-based allocation.
None identified in the reviewed text
No congressionally directed spending for particular recipients or places was identified in the complete supplied introduced text. This conclusion is limited to that version; member disclosures and committee or conference materials were not supplied.
Narrow exceptions, exemptions, or preferential treatment that warrant a closer look.
None identified in the reviewed text
No materially narrow carve-out, special exemption, or preferential exception was identified in the complete supplied introduced text. This conclusion is limited to that version and does not establish absence in other versions or accompanying materials.
Full text preserved for this analysis. Legislative record snapshot: Jun 4, 2025. How PlainBill uses AI